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Abstract
In patients with heart failure (HF), it is important to perform exercise therapy 
with a focus on the pathophysiology of skeletal muscle. Patients with HF have 
multiple clinical symptoms due to cardiac dysfunction. Recent studies demon-
strated the mechanism and treatment strategy for HF, and multiple signaling 
pathways involved in HF result in reduced exercise capacity and skeletal muscle 
mass. On the other hand, exercise therapy for HF is known to inhibit the inflam-
matory cytokines and neurohumoral factors, and increase muscle mass. Therefore, 
in this chapter, we discuss the importance of exercise therapy for HF, with a focus 
on the pathophysiology of skeletal muscle.
Keywords: heart failure, skeletal muscle, muscle abnormality, exercise training, 
combination therapy
1. Introduction
1.1 Pathology of HF
HF is a condition characterized by cardiac decompensation due to organic or 
functional impaired pumping capacity. Reduced exercise capacity in patients with 
HF leads to numerous symptoms such as breath shortness, dyspnea, general fatigue, 
and edema in the foot [1]. One of the causes of reduced exercise capacity is the 
condition of HF. According to the JCS 2017/JHFS 2017 guidelines on the diagnosis 
and treatment of acute and chronic HF [1], HF is categorized into three groups by 
the left ventricular ejection fraction (LVEF). One is HF with LVEF <40%, termed 
heart failure with reduced ejection fraction (HFrEF). HFrEF develops due to left 
ventricular systolic dysfunction. HFrEF is a leading cause of ischemic heart disease 
and coronary sclerosis. Another group is HF with LVEF ≥50%, termed heart failure 
with preserved ejection fraction (HFpEF). HFpEF is known as diastolic dysfunction 
in HF. Diastolic dysfunction is mainly caused by hypertension. The last group is HR 
with LVEF from 40–49%, termed heart failure with mid-range ejection fraction 
(HFmrEF). HFmrEF can develop in the recovery process from HFrEF, but many 
other factors can cause HFmrEF. For example, arrhythmia with tachycardia, such 
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as atrial fibrillation, places strain on the left heart and causes HFmrEF. The exact 
mechanism of HFmrEF remains unclear.
Reduced exercise capacity in patients with HF can also cause organic and func-
tional abnormality of skeletal muscle not only due to abnormal LVEF. Patients with 
HF can lose weight due to these abnormalities of skeletal muscle. A previous study 
reported that weight loss of 7.5% over six months was an independent predictor of 
long-term mortality in patients with HF [2]. In addition to the condition of HR and 
its related skeletal muscle abnormalities, reduced exercise capacity develops slowly 
with age. On the other hand, in 1998, Rosenberg proposed the term “sarcopenia” 
to describe age-related muscle decrease. Elderly patients with HF are included in 
“secondary sarcopenia” and advanced HF patients are defined as having “cardiac 
cachexia”. The Asian definition of sarcopenia was established by the Asian Working 
Group for Sarcopenia in 2014 [3]. Sarcopenia is diagnosed by a low muscle mass and 
low muscle strength or low physical performance. Sarcopenia develops due to aging, 
undernutrition, sedentary lifestyle, and progression of inflammatory diseases, 
cancer, and chronic diseases such as HF and COPD. The reported prevalence of 
sarcopenia is between 4.1% and 11.5% in Asian older people. On the other hand, in 
2013, Fülster reported a prevalence of 19.4% among 200 ambulatory patients with 
stable chronic HF in Germany [4].
The exact mechanism of the development of sarcopenia related to HF is unclear. 
However, previous studies noted specific changes in skeletal muscle in patients with 
HF. Kinugawa et al. reported that patients with HF have skeletal muscle abnormali-
ties, including energy dysbolisms, fiber transformation from type 1 (slow-twitch 
muscle fibers) to type 2 (fast-twitch muscle fibers), and mitochondrial dysfunction 
[5]. Brown et al. demonstrated decreases in mitochondrial density, gene expression, 
and oxygenated capacity in skeletal muscle in patients with HF [6]. Using animal 
studies, Takada et al. found that chronic heart failure (CHF) model mice have a 
low level of protein expression of phosphorylated AMPKα, sirtuin-1, PGC-1, and 
mitochondrial transcription factor A (Tfam) in skeletal muscle [7].
In this review, we describe the molecular mechanisms in skeletal muscle and the 
treatment for HF.
2. Molecular mechanisms of HF
This section presents three representative skeletal muscle mechanisms unique to 
HF that cause organic and functional physical abnormalities.
2.1 Inflammatory cytokines
Inflammatory cytokines are biologically active substances that exert a variety of 
functions by signaling through specific receptors on the cell surface. Inflammatory 
cytokines include interleukin (IL)-6, interferon, tumor necrotic factor (TNF) 
family, and colony-stimulating factor. The excess secretion of inflammatory 
cytokines due to HF disrupts the anabolic catabolic balance of skeletal muscle in HF 
patients. Impaired cardiac cell and vascular endothelial cells with high stress result 
in the secretion of inflammatory cytokines and myocardial infarction. Levine et al. 
reported that HF patients have a high circulating concentration of TNF-α [8].
In 2001, Reid et al. reported that secretion of TNF-α increased the production 
of reactive oxygen species through the mitochondrial electron transport system, 
resulting in the activated ubiquitin-proteasome system through the NF-κB signal-
ing pathway [9]. This study suggested progressive skeletal muscle wasting through 
these systems in HF patients. In addition, Chojkier et al. reported that TNF- 
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α-injected mice had increased expression of nitric oxide synthase activity and the 
expression of their albumin synthesis genes was downregulated [10]. Schaap et al. 
reported that high expression of TNF-α and IL-6 led to a reduction of the quadriceps 
muscle area and grip strength in older people [11]. Langhaus et al. reported that 
the secretion of TNF-α induced appetite loss [12]. Saitoh et al. found that appetite 
loss caused malnutrition and resulted in the inhibition of protein anabolic action. 
Moreover, appetite loss was associated with a poor prognosis in HF patients in their 
study [13]. On the other hand, Hollriegel et al. reported that HF patients did not 
have high expression of atrogin-1 mRNA or protein in skeletal muscle [14]. Of note, 
there are few studies on this topic in human subjects [15]. Although TNF-α and IL-6 
activity affect muscle abnormalities in HF patients, it remains unclear how inflam-
matory cytokine families influence each other in humans.
2.2 Renin–angiotensin–aldosterone system
The accelerated renin-angiotensin-aldosterone (RAA) system leads to skeletal 
muscle dysfunction in HF patients. Angiotensinogen is produced from the liver and 
is the first substrate of the RAA system. Thereafter, renin from the juxtaglomeru-
lar apparatus of the kidney is released into the blood. Angiotensin І is produced 
from angiotensinogen by activated renin. Then, angiotensin ІІ is produced from 
angiotensin І by angiotensin-converting enzyme. Angiotensin ІІ causes vasocon-
striction and stimulates aldosterone secretion through angiotensin ІІ type 1 recep-
tor. Angiotensin ІІ causes an accumulation of fibrosis in skeletal muscle through 
transforming growth factor-β (TGF-β)-dependent signaling [16]. Activation of the 
RAA system in HF patients causes the overproduction of angiotensin ІІ. Their RAA 
system is activated regardless of the severity of HF [17]. This study also revealed 
that their renin activity is significantly higher than that in those without HF 
(3.0 ± 3.7 and 1.2 ± 1.2 ng/mL). In 2007, Cohn et al. investigated the effects of TGF-β 
neutralizing antibodies and angiotensin-receptor blockers (ARB) on skeletal muscle 
function. In this study, the intervention group using ARB had significantly reduced 
TGF-β signaling through angiotensin ІІ and improved skeletal muscle function 
[18]. TGF-β is also known as a factor that elicits apoptosis of muscle satellite cells 
during the process of repairing damaged skeletal muscles. The author suggested 
that inhibition of the angiotensin ІІ type1 receptor by ARB led to the low expression 
of TGF-β.
Fukushima et al. demonstrated that the phosphorylation of Akt (p-Akt) 
decreased in skeletal muscle from mice with HF after myocardial infarction and 
this decrease was caused by an increase in plasma angiotensin ІІ [19]. Another study 
using HF model mice found that angiotensin ІІ directly induced skeletal muscle 
abnormalities [20]. This study reported a significant decrease in the amount of 
p-Akt protein in angiotensin ІІ-treated mice. In addition, angiotensin ІІ induced 
fiber transformation from type І to type ІІ, skeletal muscle atrophy, and weight 
loss. Based on these involved factors, the RAA system is considered to elicit skeletal 
muscle dysfunction in HF. In the future, studies on increased protein catabolism by 
the RAA system need to be conducted in humans.
2.3 Autophagy
Autophagy is an intracellular system that delivers cytoplasmic substrates to 
lysosomes for subsequent degradation and removal. Autophagy is divided into 
three types depending on the mechanisms; macroautophagy, microautophagy, 
and chaperone-mediated autophagy. The research area of macroautophagy is the 
most advanced of these three types. Fasting induces the autophagy system and 
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the isolation membrane is formed. The isolation membrane elongates, engulfing 
protein aggregates and organelles within the cytoplasm, and finally forms double-
membraned structures called autophagosomes. Autophagosomes subsequently fuse 
with lysosomes to degrade their cargo by lysosomal enzymes.
Autophagy influences the muscle abnormalities in HF. There are two mecha-
nisms. First, a maladaptive response for autophagy exacerbates the condition of 
HF, resulting in reduced muscle function. For example, the decrease in Beclin 1 
expression weakens the macroautophagy system in patients with ischemic cardiac 
myopathy [21]. In contrast, Zhu et al. reported that pressure overload in mice mark-
edly increased cardiac autophagy and load-induced autophagic activity remained 
significantly high for at least 3 weeks [22]. This study reported that Beclin 1 over-
expression increased autophagic activity and promoted pathological remodeling. 
Using mice with pressure-overload heart failure, this study revealed that lysosome 
abundance calculated by measuring the lysosomal markers LAMP-1 and cathepsin 
D increased in wild-type hearts and to a greater extent in Beclin 1 transgenic hearts. 
Another study demonstrated that cardiac-specific deficiency of autophagy-related 
5, a protein required for autophagy, leads to cardiac hypertrophy in adult mice [23]. 
Therefore, HF is exacerbated by dysfunctional autophagy and results in skeletal 
muscle abnormality.
Second, cardiac autophagy may directly cause skeletal muscle atrophy regardless 
of the progression of HF. Janning et al. investigated the autophagy pathway using 
myocardial infarction model mice [24]. Their study revealed that although myoat-
rophy in the soleus muscle and plantaris muscle progressed, the expression levels 
of autophagic markers, such as GABARAPL-1 and AtG7, increased in the plantaris 
but not in the soleus muscle. This study provides evidence of autophagy signaling 
regulation in HF-induced muscle atrophy. In addition, the selective degradation 
of mitochondria is termed mitophagy. Oka et al. reported that cardiac cells are 
abundant in mitochondria and dysfunctional mitophagy leads to reduced cardiac 
function through the inflammation inside the cells [25]. It is also possible that 
mitophagy causes skeletal abnormalities.
There is increasing evidence supporting a role of autophagy in age-related dis-
ease states of the cardiovascular system. Sasaki et al. reviewed autophagy in cardio-
vascular disease [26]. Their report states that autophagy is related to age-associated 
cardiovascular diseases, HF, ischemic heart disease, cardiomyopathy, hypertension, 
and atherosclerosis. However, the mechanisms of skeletal muscle dysfunction 
caused by autophagy in HF remain unclear.
3. Exercise training as treatment for HF
Exercise training improved the reduced exercise capacity and skeletal muscle 
power due to HF in several studies. There are two types of exercise; aerobic exercise 
and resistance training (RT). Aerobic exercise induced peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC1-α) expression and improved 
insulin resistance [27]. High-intensity aerobic exercise increases the ratio of type 
1 muscle fibers. Gielen et al. investigated how the expression of cathepsin-L, E3 
ligases MuRF-1, and MaFbx changed after exercise training among HF patients, and 
compared them with healthy subjects [28]. As a result, the expression of MuRF-1 in 
HF patients was significantly higher than that in healthy subjects. In addition, after 
four weeks of exercise training, the expression of MuRF-1 mRNA in HF patients 
was reduced by 32.8% and 37.0% in people aged ≤55 years and ≥ 65 years, respec-
tively. In another study, they investigated the expression of inflammatory cytokines 
(TNF-α, IL-6, and IL-1-β) before and after exercise training in HF patients [29]. 
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Exercise training did not affect the serum levels of TNF-α, IL-6, or IL-1-β, but it 
significantly reduced the expression levels of these cytokines and iNOS (by 52%) in 
skeletal muscle. Thus, exercise training may reduce the expression of inflammatory 
cytokines and maintain high-level muscle function.
St-Jean-Pelletier et al. investigated myofiber changes and mitochondrial density 
in the vastus lateralis in healthy subjects [30]. They found an increased ratio of type 
2a myofibers and decreased mitochondrial density in people aged ≥65 years with 
low physical activity. Campos et al. investigated the effects of exercise training on 
mitochondrial dysfunction using myocardial infarction model mice [31]. This study 
suggested that the improvement in mitochondrial number, density, and oxygen-
ation by exercise training aid in recovery from cardiac dysfunction. Although 
exercise training improved mitochondrial dysfunction in HF mice model, the exact 
mechanism in HF patients remains to be elucidated.
Aerobic exercise increases the exercise capacity, and RT improves skeletal 
muscle mass and strength. Pu et al. demonstrated the effects of resistance training 
on muscle function in HF patients [32]. In their study, the improvement of knee 
extensor muscle power was 43% higher and the six-minute walking distance was 
49 m greater in HF patients than those in the control group. Another study also 
found that RT improved skeletal muscle mass and power more than aerobic exercise 
in dialysis patients [33]. Multimodal exercise programs, including aerobic exercise, 
RT, and respiratory muscle training, were reported to significantly improve dyspnea 
and the quality of life, in addition to quadriceps power and exercise time, in HF 
patients [34].
Saitoh et al. suggested that combination therapy of exercise training with 
standard drugs, such as angiotensin-converting enzyme inhibitors, beta-receptor 
blockers, ghrelin agonists, and myostatin inhibitors, is better than exercise training 
and nutritional supplements for treating cardiac sarcopenia [35]. The following 
section explains the possibility of treatment for HF using combinations of exercise 
training and other therapies (Figure 1).
3.1 Combination of nutritional supplements and exercise training
3.1.1 Amino acids and micronutrients
Sufficient nutritional supplements improve skeletal muscle dysfunction 
accompanying HF. Aquilani et al. investigated the effects of exercise training 
with 8 g of daily essential amino acids (EAA) in 21 HF patients [36]. Based on the 
cardiopulmonary exercise test, the EAA group had no change in oxygen consump-
tion but increased their exercise load. Although there was no significant change 
in the 6-minute walking distance in the control group, the EAA group increased 
their walked distance by 74 m on average. Rozentryt et al. reported that the intake 
of nutritional supplements with a high-calorie (600 kcal) and high-protein (20 g) 
diet increased the body weight by 2.0 kg at the 6-week follow-up and 2.3 kg at the 
18-week follow-up [37]. In this study, oral nutritional supplementation did not 
affect the albumin concentration or peak oxygen consumption, but reduced the 
serum level of TNF-α.
β-Hydroxy-β-methylbutyrate (HMB) is a metabolite of the amino acid leucine 
and has a positive effect on muscle protein anabolism. A study using rats reported 
that HMB supplementation resulted in greater expression of Akt, mTOR, and 
S6K1 than leucine [38]. Berk et al. investigated the effects of a mixture of HMB, 
glutamine, and arginine in advanced cancer patients. However, there were no 
significant differences in the 8-week lean body mass between the placebo and the 
HMB/Arg/Gln groups [39]. Another study examining chronic pulmonary patients 
Muscle Cell and Tissue - Novel Molecular Targets and Current Advances
6
described that, in the group receiving pulmonary rehabilitation plus an oral nutri-
tional supplement enriched with HMB, the mean and maximum handgrip and 
fat free mass significantly increased at 12 weeks [40]. The review of HMB supple-
mentation in humans suggested that this agent has positive effects in patients with 
chronic pulmonary disease, hip fracture, and AIDS- related and cancer-related 
cachexia [41], but HF was not mentioned. However, a recent study suggested that 
a high-protein oral nutritional supplement containing HMB increased the body 
weight at day 30 in HF patients [42]. As described above, protein supplementation 
for HF patients increases the body mass and improves muscle function.
In recent years, the role of microelements has gained attention. Magnesium 
insufficiency increase the risk of HF. Sasiwarang et al. examined the relationship 
between the onset of HF and magnesium concentration in healthy subjects for 
15 years [43]. Serum magnesium was inversely related to the risk of incident of 
HF. Moreover, HF patients with hypomagnesemia had high levels of IL-6 and von 
Willebrand factor (VWF). VWF is a marker for endothelial dysfunction and the 
serum level of VWF in HF patients is high. The author suggested that the magne-
sium concentration influences the inflammatory reaction. Microelements also play 
an important role in the treatment of sarcopenia [44]. Magnesium supplementation 
was reported to possibly improve the functional indices such as quadriceps torque 
[45]. In addition, the walking speed of healthy elderly women in the magnesium 
supplementation group became significantly faster than that of those in the 
control group (the supplementation group:∆ 0.21 ± 0.27 m/s, the control group ∆ 
0.14 ± 0.003). However, there are no studies on the effects of combination therapy 
of exercise training and magnesium supplementation in HF patients. As magnesium 
is commonly used for the treatment of arrhythmia and HF, it may be useful for the 
treatment of muscle dysfunction in HF.
3.1.2 Ghrelin
Ghrelin can improve the physical function of patients with HF. Ghrelin is 
produced in the fundic gland of the stomach, and stimulates gastric acid secretion 
and motility. Ghrelin has anabolic, orexigenic, and anti-inflammatory effects [46]. 
Ghrelin levels are lower in older people, especially in those with sarcopenia [47].  
Figure 1. 
It is thepossibility of treatment for HF using combinations of exercise training and other therapies. This figure 
presents the effects of exercise training added by other factors. The square box shows the other factors and the 
dotted box shows treatment effect. EAA: essential amino acids, HMB: β-Hydroxy-β-methylbutyrate, SPPB: 
short physical performance battery, RAA inhibitors: Renin-angiotensin-aldosterone inhibitors, SARM: selective 
androgen receptor modulators.
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A study on anamorelin, a selective ghrelin receptor agonist, demonstrated a signifi-
cant effect on body weight and food intake, but not on muscle strength in patients 
with cancer cachexia [48]. Nagaya et al. reported that the injection of synthesized 
ghrelin (2 μg/kg twice a day for 3 weeks) to HF patients increased the LVEF without 
adverse events, and increased the peak workload and oxygen consumption dur-
ing exercise [49]. On the other hand, rikkunshito, a Japanese herbal medicine, is a 
ghrelin potentiator. Fujitsuka et al. reviewed the promotion of ghrelin activity by 
rikkunshito [50]. Several clinical trials demonstrated that the administration of 
rikkunshito increased the plasma ghrelin levels. These studies support the potential 
use of rikkunshito for improving skeletal muscle function and exercise capacity. 
However, rikkunshito and dipotassium glycyrrhizinate are structural components 
of licorice extract. The accumulation of dipotassium glycyrrhizinate in the body 
may cause pseudo aldosteronism and exacerbate the condition of HF. Thus, rik-
kunshito should be administered carefully. The satisfactory amount of rikkunshito 
should be investigated to manage HF effectively and safely.
3.1.3 Vitamin D
Vitamin D administration improves the exercise capacity in HF patients. The 
role of vitamin D is to maintain homeostatic function of the calcium-phosphorus 
balance and regulate bone metabolism. In recent years, vitamin D was confirmed 
to play an essential role in skeletal muscle function. Vitamin D deficiency or 
mutated vitamin D receptor causes skeletal muscle atrophy [51]. Vitamin D 
receptors are involved in gene expression in skeletal muscle, and regulate muscle 
anabolism and metabolism. The receptors act on calcium channels and directly 
regulate muscle contraction. Therefore, vitamin D deficiency results in lipid 
accumulation in skeletal muscle and atrophy of type 2 myofibers. Hayakawa 
et al. reported that the administration of 1α25 (OH)2D3 to human muscle 
cells inhibited the gene expression of MaFbx and MuRF-1 [52]. Antoniak et al. 
examined the effects of combination therapy of vitamin D administration and 
exercise training in comparison with exercise training and vitamin D alone [53]. 
They found that lower extremity muscle power increased more in the combination 
therapy group than in the exercise training alone group. In addition, the score 
of the short physical performance battery, skeletal muscle power, and femur 
density increased more in the combination therapy group than in the vitamin D 
alone group.
On the other hand, a meta-analysis demonstrated that vitamin D administra-
tion reduced the levels of TNF-α, CRP, and thyroid hormone, but did not improve 
exercise performance [54]. Bauer et al. reported the effects of combination therapy 
using vitamin D and leucine-enriched whey protein on physical function in older 
people with sarcopenia [55]. The active group (n = 184) received vitamin D at 
800 IU, 20 g of whey protein, and 9 g of leucine twice a day for 13 weeks. In the 
active group, the score for the chair-stand test (1.0 second on average) and muscle 
mass (0.19 kg on average) significantly improved when compared with the control 
group. Other several studies using healthy elderly subjects reported the improve-
ment of physical functions using a combination of vitamin D and amino acids, but 
not in HF patients.
3.2 Combination with standard therapeutics for HF
Standard therapeutics for HF can improve the skeletal function in HF patients. 
This section explains the three types of medicines for HF that may be useful for 
skeletal muscle.
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3.2.1 Beta-blockers
Beta-blockers can prevent weight loss in HF patients. Beta-blockers, which have 
inhibitory action against left ventricular remodeling, are used for the treatment of 
HF and hypertension. Bisoprolol is a beta one-selective blocker and carvedilol is an 
alpha-beta blocker, and they are commonly used in the treatment of HF.
Beta-blockers were recently reported to inhibit muscle atrophy. A study using 
cancer cachexia model mice revealed that the administration of bisoprolol inhib-
ited the loss of skeletal muscle mass [56]. This study also reported that bisoprolol 
improved physical activity and oral intake. In patients with rectal cancer or small 
cell carcinoma, the administration of espindolol twice a day improved their life 
prognosis and weight loss [57].
Clark et al. investigated the effects of the administration of carvedilol on body 
weight loss in patients with HF [58]. Carvedilol was initially administered at 3.1 mg 
(twice a day) and later increased to a maximum of 25 mg per dose (twice a day). 
As a result, the administration of carvedilol resulted in body weight gain (1 kg on 
average) after one year.
Based on these studies, beta-blockers may maintain skeletal muscle quality and 
improve skeletal muscle mass in HF patients.
3.2.2  Renin-angiotensin-aldosterone (RAA) inhibitors: angiotensin converting 
enzyme inhibitors (ACEI)/angiotensin-receptor blockers (ARB)
RAA inhibitors can improve muscle function in HF patients. Angiotensin 
converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are 
commonly used for the treatment of hypertension. Saitoh et al. reported the protec-
tive action of ACEI for muscle function [59]. Several studies reported that ACEI 
prevent body weight loss due to HF, and improved muscle power and physical func-
tions [60, 61]. Sumukadas et al. investigated the effects of a combination of ACEI 
therapy and exercise training on physical functions in older people [62]. However, 
the 6-minute walk distance, score of the Short Physical Performance Battery, 
handgrip and quadriceps strength, and QOL at 10-week and 20-week follow-up did 
not improve in the intervention group. In this study, some bias was considered to 
have caused the insufficient effects of combination therapy.
RAA inhibitors have direct positive effects on muscle function in HF patients. 
Thus, high-quality studies examining both RAA inhibitors and exercise training in 
HF patients are warranted.
3.2.3 Selective androgen receptor modulators (SARM)
Testosterone may have a positive effect on skeletal muscle mass. On the 
other hand, serious side effects, such as increased risks of developing prostate 
cancer and myocardial infarction, have been reported [63]. Therefore, selective 
androgen receptor repair agents known as selective androgen receptor modula-
tors (SARM) were developed. They exert testosterone-induced muscle mass gain 
effects with less stimulation of the prostate. SARM may increase skeletal muscle 
mass in HF patients. The clinical trial SARMsMK-0773 examined their effects 
on skeletal muscle in female patients with sarcopenia [64]. Muscle mass in the 
intervention group increased significantly compared with that in the placebo 
group, but no effects on physical functions or muscle power were observed in 
this study.
No studies have investigated the effects of combination therapy of SARM and 
exercise training on skeletal muscle mass and physical function in HF patients.
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4. Conclusions
The pathophysiology of skeletal muscle in patients with HF is complex and 
remains unclear. However, recent studies clarified several points. The mechanisms 
do not function independently and instead interact with each other. In the manage-
ment of HF, it is important to assess skeletal muscle and physical functions, and to 
consider treatment combinations including exercise training, electrical stimulation, 
medicine, and supplements. Large-scale, high-quality studies are warranted to 
elucidate the pathophysiology and establish effective treatments for HF patients.
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